DAFTAR PUSTAKA

Adityan B & Thappa D (2009) Profile of acne vulgaris: A hospital-based study from South India. *IJDVL.* 75: 727-8.

All S, Shoukry NS, Maged RAE & Ayada MM (2007) Immunohistochemical expression of interleukin-8 in skin biopsies from patients with inflammatory acne vulgaris. *Diagnostic Pathol.* 4: 1-6.

Anwar A, Dewi RK, Massi MN & Yusuf I (2007) No Relationship between CYP17-34T/C polymorphism and severe acne in Makassar by sequencing method. *Dermatovenereology.* Makassar, Hasanuddin University.

Arancibia S & et al (2007) Toll-like receptors are key participants in innate immune responses. *Biol Res.* 40: 97-112.

Astuti DW (2011) Hubungan Antara menstruasi dengan angka kejadian akne vulgaris pada remaja *Fakultas Kedokteran.* Semarang, Universitas Diponegoro.

Ballanger F, Baudry P, N'Guyen J, Khammari A & Dréno B (2006) Heredity: a prognostic factor for acne. *Dermatology.* 212: 145-9.

Baran R, Chivot M, Shalita A, Lewis A & Wechsler A (2005) Acne. dalam Baran R & Maibach H (Eds.) *Textbook of cosmetic dermatology.* 3 ed. London, Taylor & Francis.

Baumann M (2002) Acne. dalam Bauman L & Weisberg E (Eds.) *Cosmetic dermatology principles and practice* New York, The McGraw-Hill Companies.

Baz K, Erdal M, Yazici A, Soymelez F, Guvenc U, Tasdelen B & Ikizoglu G (2008) Association between tumor necrosis factor-alpha gene promoter polymorphism at-308 and acne in Turkish patients. *Arch Dermatol Res.* 300: 371-6.

Burkhart C & Gottwald L (2003) Assesment of etiologic agents in acne pathogenesis. *Skin Med.* 2: 222-8.

Capitanio B, Sinagra JL, Ottaviani M, Berdignon V, Amantea A & Picaedo M (2009) Acne and smoking. *Dermato-Endocrinology.* 3: 129-35.

Chiu A, Chon S & Kimball A 2003 The response of skin disease to stress. *Arch Dermatol Res.* 139: 897-900.

Chuh AA, Zawar V, Wong WC & Lee A (2004) The association of smoking and acne in men in Hong Kong and in India: a retrospective case–control study in primary care settings. *Clin Exp Dermatol.* 29: 597-99.

Collier CN & et al (2008) The prevalence of acne in adult 20 years and older. *J Am Acad Dermatol.* 58: 56-9.

Cordain L (2005) Implications for the role of diet in acne. *Semin Cutan Med Surg.* 24: 84-91.

Cordain L, Lindeberg S, Hurtado M, Hill K, Eaton S & Brand-Miller J (2002) Acne vulgaris a disease of western civilization. *Arch Dermatol.* 138: 1584-90.

Crowther J (2001) The ELISA Guidebook*,* New Jersey, Humana Press.

Dessinioti C & Katsambas AD (2010) The role of *Propionibacterium acnes* in acne pathogenesis: fact and controversies. *Clin Dermatol.* 28: 2-7.

Do T, Zarkhin S, Orringer JS & Nemeth S (2008) Computer assisted aligment and tracking of acne lesion indicated that most inflammatory lesions arise from comedones and de novo. *J Am Acad Dermatol.* 603-8.

Dreno B & Poli F (2003) Epidemiology of Acne. *Dermatology.* 206: 7-10.

Farrar MD & Ingham E 2004 Acne: Inflamation. *Clin Dermatol.* 22: 380-4.

Feldman S, Careccia R, Barham K & Hancox J (2004) Diagnosis and Treatment of Acne. *Am Fam Physician.* 69: 2123-30.

Ferdowsian HR & Levin S (2010) Does diet really affect acne? *Skin Therapy.* 15: 4-5.

Fulton J, Plewig G & Kligman A (1969) Effect of chocolate on acne vulgaris. *JAMA.* 210: 1-4.

Gawkrodger D (2003) Dermatology an illustrated colour text. New york, Churchill Livingstone.

Ghoname NF, Amin AM, Ismail MA, Shaaban DM & Hassan AM (2008) Expression of Toll Like Receptor-2, Human β-Defensin-2 and Interleukin-8 in Inflammatory Acne Vulgaris. *Egypt J of Med Microbiol.* 17.

Gilbert B (2004) Targeting inflammatory mediators in acne. *Dermatol Times.* 25: S38.

Gollnick H, Cunliffe W, Bearson D, Dreno B & Finlay A (2003) Management of acne a report from a global alliance to improve outcomes in acne. *J Am Acad Dermatol.* 49: S1-38.

Goulden V, McGeown C & Cunliffe W (1999a) The familial risk of adult acne: a comparison between first-degree relatives of affected and unaffected individuals. *Br J Dermatol.* 141: 297-300.

Goulden V, Stables G & Cunliffe W (1999b) Prevalence of facial acne in adults. *J Am Acad Dermatol.* 41: 577-80.

Graham GM, Farrar MD, Cruse-Sawyer J, Holland KT & Ingham E (2004) Proinflammatory cytokine production by human keratinocytes stimulated with Propionibacterium acnes and P. acnes GroEL. *Br J Dermatol* 150: 421-8.

Guy W (2002) Acne vulgaris. *Br J Medic.* 325: 475-9.

Halvorsen JA, Dalgard F, Thoresen M, Bjertness E & Lien L (2009) Is the association between acne and mental distress influenced by diet?

Results from a cross-sectional population study among 3775 late adolescents in Oslo, Norway. *BMC Public Health.* 9: 1-8.

Hamza T, Barnett J & Li B (2010) Interleukin 12 a Key Immunoregulatory Cytokine in Infection Applications. *Int J Mol Sci.* 11: 789-806.

Harper J (2004) An update on the pathogenesis and management of acne vulgaris. *J Am Acad Dermatol.* 51: S36-8.

Hassanzadeh P, Bahmani M & Mehbrani D (2008) Bacterial resistence to antibiotics in acne vulgaris: an in vitro study. *Indian J Dermatol* 53: 122-4.

He L & et al (2006) The relationship between CYP17-34T/C polymorphism and acne in Chinese subjects revealed by sequencing. *Dermatology.* 212: 338-42.

Herane MI & Ando I (2003) Acne in infancy and acne genetics. *Dermatol.* 206: 24-8.

Heymann W (2006) Toll-like receptors in acne vulgaris. *J Am Acad Dermatol.* 55: 691-2.

IDEXX L (2007) ELISA Technical Guide. USA.

James W, Berger T & Elston D (2006) Acne. *Andrew's diseases of the skin clinical dermatology.* Philadelphia, Saunders Elsevier.

Jeremy A, Holland DB, Roberts SG, Thomson KF & Cunlife WJ (2003) Inflammatory events are involved in acne lesion initiation. *J Invest Dermatol.* 121: 20-7.

Kaminer M & Gilchrest B (1995) The many faces of acne. *J Am Acad Dermatol.* 32: S6-14.

Kim J (2005) Review of the Innate Immune Response in Acne vulgaris: Activation of Toll-Like Receptor 2 in Acne Triggers Inflammatory Cytokine Responses. *Dermatology.* 211: 193-8.

Kim J & et al (2002) Activation of Toll-Like Receptor 2 in Acne Triggers Inflammatory Cytokine Responses. *J Immunol.* 169: 1535-41.

Klaz I, Kochba I, Shohat T, Zarka S & Brenner S (2006) Severe acne vulgaris and tobacco smoking in young men. *J Invest Dermatol.* 126: 1749-52.

Koreck A & et al (2006) TLR2 and TLR4 Polymorphisms are not associated with acne vulgaris. *Dermatology.* 213.

Kresno BS (2010) Teknik laboratorium yang umum digunakan dalam imunologi. *Imunologi: Diagnosis dan Prosedur Laboratorium.* Jakarta, Badan Penerbit FKUI.

Kubba R & et al (2009) Factors precipitating or aggravating acne. *IJDVL.* 75: S10-2.

Law MP, Chuh AA, Molinarit N & Lee A (2009) An investigation of the association between diet and occurrence of acne: a rational approach from a traditional Chinese medicine perspective. *Clin Exper Dermatol.* 35: 31-5.

Leyden J (1998) Topical treatment of acne vulgaris: retinoid and cutaneous irritation. *J Am Acad Dermatol.* 38: S1-4.

Liao DC (2003) Management of Acne. *Fam J Pract.* 52: 43.

Loveckova Y & Havlíkovab I (2002) A microbiological approach to acne vulgaris. *Biomed.* 146: 29-32.

Maria I (2003) Acne in infancy and acne genetics. *Dermatology.* 24-28.

Mills C, Peters T & Finlay A (1993) Does smoking influence acne? *Clin Exp Dermatol.* 18: 100-1.

Mills O, Porte M & Kligman A (1978) Enhancement of comedogenic substances by ultraviolet radiation. *Br J Dermatol.* 98: 145-50.

Munawar S, Afzal M, Rizvi F & Chaudry M (2009) Precipitating factors of acne vulgaris in females. *An Pak Inst Med Sci.* 5: 104-7.

Murphy T, Cleveland M, Kulesza P, Magram J & Muerphy K (1995) Regulation of Interleukin 12 p40 Expression through an NF-kB Half-Site. *Mol Cell Bio.* 15: 5258-67.

Nagy I, Pivarcsi A, Koreck A, Sze´ M, Urba´ E & Keme´ L (2005) Distinct Strains of Propionibacterium acnes Induce Selective Human b-Defensin-2 and Interleukin-8 Expression in human Keratinocytes Through Toll-Like Receptors. *J Invest Dermatol.* 124: 931-8.

Palma RA, Castrilion RL, Padilla DC, Chafez FSJ & Encinas PG (2007) Identification of IL-8, IL-1β and TNF-alpha in lession of patients with infllamatory acne vulgaris. *Dermatol revista med.* 51: 43-50.

Pappas A, Johnsen S, Liu JC & Eisinger M (2009) Sebum analysis of individuals with and without acne. *Dermato-Endoc.* 1:3: 157-61.

Pawin H & et al (2004) Physiopathology of acne vulgaris: recent data, new understanding of the treatments. *Eur J Dermatol.* 14: 4-12.

Perkins AC, Cheng CE, Hillebran GG, Miyamoto K & Kimball AB (2011) Comparison of the epidemiology of acne vulgaris among Caucasian, Asian, Continental Indian and African American women. *JEADV.* 25: 1054-60.

Petry V & Gaspari A (2009) Toll-like receptors and dermatology. *Int J Dermatol.* 48: 558-70.

Pierce B (2010) ELISA technical guide and protocols USA, Thermo Scientific.

Rombouts S, Nijsten T & Lambert J (2007) Cigarette smoking and acne in adolescents: results from a cross-sectional study. *JEADV.* 21: 326-33.

Schaefer O (1971) When the eskimo comes to town. *Nutr Today.* 6: 8-16.

Shen Y & et al (2012) Prevalence of Acne Vulgaris in Chinese Adolescents and Adults: A Community-based Study of 17,345 Subjects in Six Cities. *Acta Derm Venereol.* 92: 40-4.

Sidiropoulos M (2006) Back to basic: acne vulgaris:pathogenesis and retinoid therapy. *Univ Toronto Medic J.* 83: 94-5.

Simpson N & Cunliffe W (2007) Disorders of the sebaceous glands. dalam Burns T, Breathnach S, Cox N & Griffiths C (Eds.) *Rook's textbook of dermatology.* 8 ed. Oxford, Blackwell Publishing.

Sitohang BS (2011) Patogenesis terkini akne vulgaris. *MDVI.*

Smith KE & Fenske NA (2000) Cutaneous manifestation of alcohol abuse. *J Am Acad Dermatol.* 43: 1-18.

Smith R, Mann N, Braue A, Makelainen H & Varigos G (2007) A low-glycemicload diet improves symptoms in acne vulgaris patients: a randomized controlled trial. *Am J Clin Nutr.* 86: 107-15.

Smith RN, Mann NJ, Braue A, Ma¨kela¨inen H & Varigos GA (2007) The effect of a high-protein, low glycemiceload diet versus a conventional, high glycemiceload diet on biochemical parameters associated with acne vulgaris: A randomized, investigator-masked, controlled trial. *J Am Acad Dermatol.* 57: 247-56.

Spencer EH, Ferdowsian HR & Barnard ND (2009) Diet and acne: a review of the evidence. *Int J Dermatol.* 48: 339-47.

Sugisaki H & et al (2009) Increased interferon-γ, interleukin-12p40 and IL-8 production in Propionibacterium acnes-treated peripheral blood cells from patient with acne vulgaris. Host response but not bacterial species is the determinant factor of the disease. *Dermatol Sci.* 55: 47-52.

Sylvia L (2010) Hubungan antara jenis mikroorganisme yang ditemukan pada lesi akne dengan bentuk lesi akne di RS. Dr. M. Djamil Padang. Fakultas Kedokteran Padang, Universitas Andalas.

Tan HH, Tan AW, Barkham T, Yan XY & Zhu M (2007) Community-based study of acne vulgaris in adolescent in Singapore. *Br J Dermatol.* 157: 547-51.

Till A, Goutden V, Cunliffe W & Holland K (2000) The cutaneous microflora of adolescent, late-onset acne patients does not differ. *Br J Dermatol.* 142.

Toyoda M & Morohashi M (2003) New aspect in acne inflammation. *Dermatol.* 206: 17-23.

Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. *J Immunol.* 3: 146.

Vowel B, Yang S & Leyden J (1995) Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes: implication for chronic inflammatory acne. *Infect Immunol.* 63: 3158-65.

Wang ZY, Li K, Qiu PP, Qiu HF, Shu CM & Gau Y (2011) Expression of TLR-2 in peripheral blood mononuclear cells and its correlation with interleukin-8 and tumor necrosis factor-α in patients with acne vulgaris. *Chin J Dermatol.* 44.

Webster G (2007) Overview of the Pathogenesis of Acne. dalam Webster G & Rawlings A (Eds.) *Acne and its therapy.* New York, Informa healthcare.

Yosipovitsh G & et al (2007) Study of Psychological Stress, Sebum Production and Acne Vulgaris in Adolescents. *Acta Derm Venereol.* 87: 135-9.

Zaenglein A, Graber EM, Thiboutot DM & Strauss JS (2008) Acne Vulgaris and Acneiform Eruptions. dalam Wolff K, Goldsmith LA & Katz SI (Eds.) *Fizpatrick's Dermatology in General Medicine.* 7 ed. New York, Mc Graw Hill.

Zhang H & et al (2008) Risk factors for sebaceous gland diseases and their relationship to gastrointestinal dysfunction in Han adolescents. *J Dermatol.* 35: 555-61.

Zouboulis C (2010) Modern aspects of acne pathogenesis. *JDDG*. 8: S7–S14

Zouboulis C & et al (2008) Frontiers in sebaceous gland biology and pathology. *Exp Dermatol.* 17: 542-51.

Zouboulis C & Bohm M (2004) Neuroendocrine regulation of sebocytes - a pathogenetic link between stress and acne. *Exp Dermatol.* 13: 31-5.

Zouboulis C & et al (2005) What is the pathogenesis of acne? *Exp Dermatol.* 14: 143-52.

Lampiran 1

REKOMENDASI PERSETUJUAN ETIK
Nomor : 0761/H4.8.4.5.31/PP36-KOMETIK/2013

Komisi Etik Penelitian Kesehatan Fakultas Kedokteran Universitas Hasanuddin, setelah melalui pembahasan dan penilaian, pada rapat tertanggal **3 April 2013**, telah memutuskan, protokol penelitian berjudul:

Perbandingan Kadar Interleukin-12 Lokal dan Sistemik pada Penderita Akne Vulgaris Berat

dengan Peneliti Utama: **dr. Ida Rachmawaty Shabir**

No. Register | U | H | 1 | 3 | 0 | 3 | 0 | 1 | 2 | 0 |

yang diterima pada tanggal: **18 Maret 2013**

Perbaikan diterima tanggal: **22 April 2013**

dapat disetujui untuk dilaksanakan di **RS dr. Wahidin Sudirohusodo** dan **RS Jejaring, Laboratorium Mikrobiologi FKUH di Makassar.**
Persetujuan Etik ini berlaku sejak tanggal ditetapkan sampai dengan batas waktu pelaksanaan penelitian.

Pada akhir penelitian, **laporan pelaksanaan penelitian** harus diserahkan kepada KEPK Fakultas Kedokteran Unhas. Jika ada perubahan protokol dan /atau perpanjangan penelitian, harus mengajukan kembali permohonan kajian etik penelitian (amandemen protokol).

Makassar, 10 Mei 2013

Komisi Etik Peneitian Kesehatan Fak. Kedokteran Unhas

Ketua

Prof. Dr. dr. Suryani As'ad, M.Sc, Sp.GK
NIP 19600504 1986 01 2 002

FORMULIR PERSETUJUAN MENGIKUTI PENELITIAN
SETELAH MENDAPAT PENJELASAN

Saya, yang bertanda tangan dibawah ini:

Nama : _____

Umur : _____

Alamat : _____

Telepon : _____

Setelah mendengar/membaca dan mengerti penjelasan yang diberikan mengenai tujuan, manfaat apa yang akan dilakukan dalam penelitian ini, bersama ini menyatakan kesediaan saya secara sukarela tanpa paksaan mengikuti penelitian ini dan mentaati semua prosedur yang akan dilakukan dalam penelitian ini.

Saya mengerti bahwa prosedur dengan cara pengambilan darah pada pembuluh darah di lipatan siku bagian depan, kemungkinan bisa menimbulkan akibat yang tidak diinginkan seperti ketidaknyamanan atau infeksi namun saya yakin tindakan pemeriksaan akan dilakukan secara bebas hama dan dengan penuh kehati-hatian oleh petugas yang terlatih untuk mencegah hal-hal yang tidak diinginkan.

Saya tahu bahwa keikutsertaan saya ini bersifat sukarela tanpa paksaan, sehingga saya bisa menolak ikut atau mengundurkan diri dari penelitian ini tanpa kehilangan hak saya untuk mendapat pelayanan kesehatan. Saya juga berhak bertanya atau meminta penjelasan kepada peneliti bila masih ada hal yang belum jelas atau masih ada hal yang ingin saya ketahui tentang penelitian ini.

Saya mengerti bahwa semua biaya yang dikeluarkan sehubungan dengan penelitian ini ditanggung oleh peneliti. Demikian juga biaya perawatan dan pengobatan bila terjadi hal-hal yang tidak diinginkan akibat penelitian ini, akan dibiayai oleh peneliti.

Saya percaya bahwa keamanan dan kerahasiaan data penelitian akan terjamin dan saya dengan ini menyetujui semua data yang dihasilkan pada penelitian ini untuk disajikan dalam bentuk lisan maupun tulisan.

Bila terjadi perbedaan pendapat di kemudian hari, kami akan menyelesaikannya secara kekeluargaan.

Makassar........................2013

	NAMA	TANDA TANGAN	TGL/BLN/THN
Klien	....	....	....
Saksi 1	....	....	....
Saksi 2	....	....	....

Tempat memperoleh tambahan informasi
Nama   : dr. Ida Rachmawaty Shabir
Alamat : Jl. Abd. Dg. Sirua lorong swadaya mas No. 16A
Telpon : 081355432285

Penanggung Jawab Medis
Nama   : Dr. dr. Anis Irawan Anwar, Sp.KK(K)
Alamat : Jln. Sundai Saddang Baru blok A10 , Makassar
Telpon : 0811412678/04115012566

DISETUJUI
Komisi Etik Penelitian Kesehatan
FK UNHAS Tgl ………………….

Lampiran 3

KUISIONER PENELITIAN

PERBANDINGAN KADAR INTERLEUKIN-12 LOKAL DAN SISTEMIK PADA AKNE VULGARIS BERAT

No. Urut　　:　　　　　　　　　　Makassar, ... 2013

Nama　　　:

Alamat　　:

Umur　　　:　　Tahun

Nomor Telp　:

Jenis Kelamin:　☐　Pria　　　　☐　Wanita

Pendidikan　:　☐　SD　　　　☐　SMP

　　　　　　　☐　SMA/Sederajat　☐　Akademi / Sarjana

　　　　　　　☐　Tidak sekolah

Pekerjaan　:　☐　Ibu rmh tangga　☐　Profesional

　　　　　　　☐　ABRI/Polisi　　☐　Pegawai negeri

　　　　　　　☐　Wiraswasta　　☐　Karyawan swasta

　　　　　　　☐　Lainnya

Aktivitas rutin:　☐　Dalam ruangan　☐　Luar ruangan

Suku : ☐ Makassar ☐ Bugis

☐ Mandar ☐ Toraja

☐ Enrekang ☐ Jawa

☐ Palopo ☐ Lainnya

Lingkungan kerja : ☐ Stres

☐ Tidak ada

Sering tidaknya memencet jerawat : ☐ Ya ☐ Tidak

Suka mengkonsumsi makanan pedas: ☐ Ya ☐ Tidak

Merokok : ☐ Ya ☐ Tidak

Alkohol : ☐ Ya ☐ Tidak

Riwayat Keluarga ☐ Ayah ☐ Ibu
yang sedang
menderita Akne : ☐ Kakak/adik

Kebiasaan makan dalam : Kacang ☐ Cokelat ☐
1 bulan terakhir
Makana ☐ Lainnya ☐
Berminyak

Riwayat Akne : .... tahun .... bulan

Tingkat Akne : ☐ Berat

- Jumlah komedo :
- Lesi inflamasi :
- Lesi total :
- Kista :

Riwayat keluhan lainnya   :
Apakah saat ini sedang menderita penyakit infeksi lainnya:

☐   Ya. Sebutkan……………………

☐   Tidak

LAMPIRAN 4

No	Kode Sampel	Nama	Umur	Sex	Aktivitas	Kultur	Alkohol	Stres	Makan minyak	Kacang	Coklat	M.pedas	Riw bpk	Riw ibu	Saudara	Merokok	Serum	Swab	Suku
1	SR.01	Risnawati	23	1	1	Staphylococcus aureus	2	1	1	2	2	1	2	1	1	2	80.8960691	17.185001	Makassar
2	SR.03	Fitriani	28	1	1	Staphylococcus epidermidis	2	1	1	2	2	1	2	2	2	2	67.35149	11.541818	Bugis
3	SR.04	Fatima	15	1	2	Enterobacter agglumerans	2	1	1	1	1	1	2	2	2	2	60.3796326	14.671567	Makassar
4	SR.07	Inha	20	1	1	Alkaligenes faecalis	2	2	1	1	1	1	2	2	2	2	110.768286	14.671567	Makassar
5	SR.08	Kurnia	17	2	2	Providencia alklalifaesen	2	1	1	2	1	2	1	2	2	1	118.085501	15.927213	Toraja
6	SR.09	Iman	18	2	2	Klabsiella pneumonia	2	1	1	2	2	1	2	2	2	1	88.559865	21.604116	Makassar
7	SR.10	Alif Iriyanto	16	2	1	Klabsiella pneumonia	2	1	1	2	1	1	1	2	2	2	173.631112	22.237559	Bugis
8	SR.11	Rahman Ibrahim	16	2	2	Enterobacter agglumerans	1	1	1	2	2	1	2	1	2	1	210.308448	17.814697	Bugis
9	SR.13	Taufik	21	2	2	Enterobacter agglumerans	2	1	1	1	2	2	2	2	2	2	82.5335465	14.044547	Makassar
10	SR.14	Yudiaman	18	2	2	Providencia alklalifaesen	2	1	1	2	2	2	1	2	2	2	28.8342149	14.044547	Bugis
11	SR.16	Clanssa	19	1	1	Providencia stuarti	2	1	1	2	2	1	2	1	2	2	14.4687728	14.044547	Makassar
12	SR.17	Septian	18	2	2	Alkaligenes faecalis	2	1	1	2	2	2	2	2	2	2	69.5064947	15.299123	Toraja
13	SR.18	Muh.Nur Qayyum	15	2	1	Alkaligenes faecalis	2	1	1	2	2	1	2	1	2	2	115.265412	16.55584	Makassar
14	SR.19	M. Amir	15	2	2	Staphylococcus aureus	2	2	1	2	2	1	2	2	2	2	98.4964798	30.521027	Bugis
15	SR.24	Muchlis B	16	2	2	Staphylococcus aureus	2	2	1	2	2	1	2	2	2	2	119.215557	15.927213	Bugis
16	SR.28	M.Nur Syamsir ali	15	2	2	Staphylococcus aureus	2	1	2	2	2	1	2	2	2	2	111.329416	14.671567	Makassar
17	SR.33	Nur Maulana	18	2	2	Enterobacter agglumerans	2	1	2	1	2	2	2	2	2	2	76.5421681	14.044547	Bugis
18	SR.36	Ahmad	23	2	2	Staphylococcus aureus	1	1	1	2	2	1	1	2	2	1	158.909834	17.185001	Makassar
19	SR.37	Dewi	24	1	2	Staphylococcus aureus	2	1	2	1	2	1	2	2	2	2	144.947198	17.185001	Makassar
20	SR.38	Ibnu	15	2	2	Alkaligenes faecalis	2	1	1	2	2	1	2	2	2	1	140.329948	14.671567	Makassar
21	SR.39	Anna N	17	1	1	Staphylococcus epidermidis	2	1	1	2	2	1	1	2	2	2	58.2442636	14.044547	Makassar
22	SR.40	Auliatul	17	1	1	Staphylococcus aureus	2	1	2	2	1	1	2	2	2	2	113.014539	15.927213	Flores
23	SR.41	Nurul	15	1	1	Alkaligenes faecalis	2	1	1	1	2	1	2	2	2	2	71.6661196	25.412804	Makassar
24	SR.42	Nurlela	31	1	1	Staphylococcus aureus	2	1	1	2	2	1	2	2	1	2	118.085501	12.166697	Bugis
25	SR.43	Irmawaty	25	1	2	Staphylococcus aureus	2	1	1	2	2	1	2	2	2	2	47.1093759	18.444929	Makassar
26	SR.45	St.Fatimah	17	1	1	Alkaligenes faecalis	2	1	1	2	2	2	2	2	1	2	84.1736228	17.814697	Bugis
27	SR.46	Hasrawati	23	1	2	Alkaligenes faecalis	2	1	1	1	2	1	2	2	2	2	80.3508208	27.962633	Bugis
28	SR.47	Anriyan	16	2	2	Enterobacter agglumerans	2	1	1	2	1	2	1	2	2	2	129.438045	22.871538	Mandar
29	SR.48	Nasrawati	17	1	1	Enterobacter agglumerans	2	2	1	1	1	1	2	2	1	2	70.0459678	17.185001	Bugis
30	SR.49	Yulianti	26	1	2	Providencia stuarti	2	2	1	1	2	1	2	2	2	2	68.9673104	18.444929	Toraja
31	SR.50	Ilham	22	2	1	Providencia alklalifaesen	2	1	1	2	2	1	2	2	2	2	66.2757202	20.338836	Bugis

32	2	Aulika	18	1	2	Alkaligenes faecalis	2	2	1	2	2	1	1	2	2	2	52.9260543	19.075696	Bugis
33	3	Nur alfianti	23	1	1	Enterobacter agglumerans	2	1	2	1	1	1	2	2	1	2	79.2611905	14.671567	Bugis
34	4	Akbar	22	2	2	Staphylococcus aureus	2	1	1	2	2	1	2	2	1	2	82.5335465	12.792112	Bugis
35	7	Mirnawati	21	1	2	Providencia stuarti	2	1	1	2	2	1	2	2	1	2	67.889808	15.927213	Makassar
36	8	Hasriana	30	1	2	Providencia alklalifaesen	2	1	1	1	2	1	2	2	1	2	67.35149	14.671567	Makassar
37	9	Fitriani	25	1	1	Staphylococcus aureus	2	1	1	1	1	1	2	2	1	2	64.1276457	18.444929	Bugis
38	13	Habia	31	1	1	Enterobacter agglumerans	2	1	2	1	2	2	2	2	1	2	6.86612542	15.299123	Bugis
39	14	Sri	31	1	2	Staphylococcus aureus	2	1	1	2	2	1	2	2	1	2	54.5184851	18.444929	Makassar
40	16	Madzait	19	2	1	Providencia stuarti	1	1	1	2	2	1	2	1	1	1	72.2067477	19.075696	Bugis

1 = iya, perempuan, dalam ruangan
2 = tidak, laki-laki, luar ruangan

Lampiran 5

One-Sample Statistics

	N	Mean	Std. Deviation	Std. Error Mean
serum	40	88.1353	41.05640	6.49159

One-Sample Test

	Test Value = 1.9					
					95% Confidence Interval of the Difference	
	t	Df	Sig. (2-tailed)	Mean Difference	Lower	Upper
serum	13.284	39	.000	86.23530	73.1048	99.3658

One-Sample Statistics

	N	Mean	Std. Deviation	Std. Error Mean
serum	40	88.1353	41.05640	6.49159

One-Sample Test

	Test Value = 52					
					95% Confidence Interval of the Difference	
	t	Df	Sig. (2-tailed)	Mean Difference	Lower	Upper
serum	5.566	39	.000	36.13530	23.0048	49.2658

One-Sample Statistics

	N	Mean	Std. Deviation	Std. Error Mean
serum	40	88.1353	41.05640	6.49159

One-Sample Test

	Test Value = 77					
					95% Confidence Interval of the Difference	
	t	Df	Sig. (2-tailed)	Mean Difference	Lower	Upper
serum	1.715	39	.094	11.13530	-1.9952	24.2658

One-Sample Statistics

	N	Mean	Std. Deviation	Std. Error Mean
swab	40	17.3216	4.05086	.64050

One-Sample Test

	Test Value = 121					
					95% Confidence Interval of the Difference	
	t	Df	Sig. (2-tailed)	Mean Difference	Lower	Upper
swab	-161.872	39	.000	-103.67838	-104.9739	-102.3829

One-Sample Statistics

	N	Mean	Std. Deviation	Std. Error Mean
swab	40	17.3216	4.05086	.64050

One-Sample Test

	Test Value = 520					
					95% Confidence Interval of the Difference	
	t	Df	Sig. (2-tailed)	Mean Difference	Lower	Upper
swab	-784.825	39	.000	-502.67838	-503.9739	-501.3829

Group Statistics

	VAR00001	N	Mean	Std. Deviation	Std. Error Mean
serum	1.00	40	88.1353	41.05640	6.49159
	2.00	40	17.3216	4.05086	.64050

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
serum	Equal variances assumed	47.667	.000	10.856	78	.000	70.81368	6.52311	57.82717	83.80019
	Equal variances not assumed			10.856	39.759	.000	70.81368	6.52311	57.62750	83.99986

Group Statistics

	Sex	N	Mean	Std. Deviation	Std. Error Mean
swab	1.00	22	16.9654	3.79133	.80831
	2.00	18	17.7570	4.41859	1.04147

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
swab	Equal variances assumed	.693	.410	-.610	38	.546	-.79168	1.29794	-3.41922	1.83586
	Equal variances not assumed			-.601	33.739	.552	-.79168	1.31835	-3.47164	1.88829

Group Statistics

	aktivitas	N	Mean	Std. Deviation	Std. Error Mean
swab	1.00	17	16.8598	3.55190	.86146
	2.00	23	17.6629	4.43031	.92378

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	Df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
swab	Equal variances assumed	.284	.597	-.615	38	.542	-.80308	1.30611	-3.44716	1.84101
	Equal variances not assumed			-.636	37.699	.529	-.80308	1.26313	-3.36082	1.75467

Group Statistics

	alkohol	N	Mean	Std. Deviation	Std. Error Mean
swab	1.00	3	18.0251	.96275	.55585
	2.00	37	17.2646	4.20486	.69127

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means							
										95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
swab	Equal variances assumed	2.126	.153	.309	38	.759	.76055	2.46043	-4.22032	5.74143
	Equal variances not assumed			.857	11.449	.409	.76055	.88703	-1.18248	2.70359

Group Statistics

	stres	N	Mean	Std. Deviation	Std. Error Mean
swab	1.00	34	16.9717	3.68559	.63207
	2.00	6	19.3042	5.72650	2.33783

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means							
										95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference		Lower	Upper
swab	Equal variances assumed	2.126	.153	.309	38	.759	.76055	2.46043		-4.22032	5.74143
	Equal variances not assumed			.857	11.449	.409	.76055	.88703		-1.18248	2.70359

Group Statistics

	minyak	N	Mean	Std. Deviation	Std. Error Mean
swab	1.00	34	17.6784	4.28105	.73419
	2.00	6	15.2998	1.12362	.45872

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means							
										95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
swab	Equal variances assumed	3.764	.060	1.339	38	.188	2.37857	1.77576	-1.21628	5.97341
	Equal variances not assumed			2.748	31.805	.010	2.37857	.86571	.61474	4.14239

Group Statistics

	kacang	N	Mean	Std. Deviation	Std. Error Mean
swab	1.00	13	17.4392	4.42285	1.22668
	2.00	27	17.2650	3.94658	.75952

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means							
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
swab	Equal variances assumed	.114	.738	.126	38	.901	.17422	1.38508	-2.62973	2.97816
	Equal variances not assumed			.121	21.506	.905	.17422	1.44278	-2.82192	3.17035

Group Statistics

	coklat	N	Mean	Std. Deviation	Std. Error Mean
swab	1.00	9	17.4009	3.18491	1.06164
	2.00	31	17.2986	4.31566	.77512

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means					95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
swab	Equal variances assumed	.258	.615	.066	38	.948	.10231	1.55378	-3.04317	3.24778
	Equal variances not assumed			.078	17.478	.939	.10231	1.31449	-2.66525	2.86986

Group Statistics

	pedas	N	Mean	Std. Deviation	Std. Error Mean
swab	1.00	32	17.6100	4.26509	.75397
	2.00	8	16.1682	2.99390	1.05850

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means					95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
swab	Equal variances assumed	.778	.383	.898	38	.375	1.44181	1.60522	-1.80779	4.69142
	Equal variances not assumed			1.109	15.031	.285	1.44181	1.29958	-1.32766	4.21129

Group Statistics

	rayah	N	Mean	Std. Deviation	Std. Error Mean
swab	1.00	7	17.9123	3.62960	1.37186
	2.00	33	17.1963	4.17569	.72689

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means							
										95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
swab	Equal variances assumed	.005	.947	.420	38	.677	.71598	1.70375	-2.73308	4.16503
	Equal variances not assumed			.461	9.699	.655	.71598	1.55254	-2.75792	4.18988

Group Statistics

	ribu	N	Mean	Std. Deviation	Std. Error Mean
swab	1.00	5	16.9352	1.86530	.83419
	2.00	35	17.3768	4.28815	.72483

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
swab	Equal variances assumed	2.122	.153	-.225	38	.823	-.44167	1.96069	-4.41088	3.52754
	Equal variances not assumed			-.400	11.546	.697	-.44167	1.10510	-2.86003	1.97669

Group Statistics

	rsdr	N	Mean	Std. Deviation	Std. Error Mean
swab	1.00	12	16.1399	2.26220	.65304
	2.00	28	17.8281	4.55313	.86046

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means							
										95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
swab	Equal variances assumed	3.421	.072	-1.215	38	.232	-1.68820	1.38921	-4.50052	1.12412
	Equal variances not assumed			-1.563	36.962	.127	-1.68820	1.08021	-3.87699	.50059

Group Statistics

	rokok	N	Mean	Std. Deviation	Std. Error Mean
swab	1.00	6	17.7130	2.43829	.99543
	2.00	34	17.2525	4.29645	.73683

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means							
										95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
swab	Equal variances assumed	1.187	.283	.254	38	.801	.46051	1.81566	-3.21511	4.13613
	Equal variances not assumed			.372	11.459	.717	.46051	1.23847	-2.25207	3.17309

Group Statistics

	sex	N	Mean	Std. Deviation	Std. Error Mean
serum	1.00	22	71.9732	31.07657	6.62555
	2.00	18	107.8890	43.85015	10.33558

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	T	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
serum	Equal variances assumed	2.664	.111	-3.027	38	.004	-35.91583	11.86592	-59.93714	-11.89453
	Equal variances not assumed			-2.925	29.773	.007	-35.91583	12.27689	-60.99662	-10.83504

Group Statistics

	stres	N	Mean	Std. Deviation	Std. Error Mean
serum	1.00	34	88.3821	43.42095	7.44663
	2.00	6	86.7366	26.48840	10.81384

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means							
										95% Confidence Interval of the Difference	
		F	Sig.	t	Df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
serum	Equal variances assumed	.799	.377	.089	38	.929	1.64551	18.41580	-35.63533	38.92636
	Equal variances not assumed			.125	10.508	.903	1.64551	13.12980	-27.41882	30.70985

Group Statistics

	alkohol	N	Mean	Std. Deviation	Std. Error Mean
serum	1.00	3	147.1417	69.79890	40.29842
	2.00	37	83.3510	35.23869	5.79320

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means							
										95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
serum	Equal variances assumed	2.778	.104	2.807	38	.008	63.79068	22.72296	17.79045	109.79091
	Equal variances not assumed			1.567	2.083	.253	63.79068	40.71270	-104.82562	232.40698

Group Statistics

	rokok	N	Mean	Std. Deviation	Std. Error Mean
serum	1.00	6	131.4001	50.15869	20.47720
	2.00	34	80.5003	34.79247	5.96686

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means							
										95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference		Lower	Upper
serum	Equal variances assumed	1.483	.231	3.092	38	.004	50.89972	16.46313		17.57186	84.22758
	Equal variances not assumed			2.386	5.879	.055	50.89972	21.32883		-1.55219	103.35163

Group Statistics

	minyak	N	Mean	Std. Deviation	Std. Error Mean
serum	1.00	34	88.0427	40.65257	6.97186
	2.00	6	88.6601	47.33014	19.32245

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means							
										95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
serum	Equal variances assumed	.095	.760	-.034	38	.973	-.61742	18.41746	-37.90163	36.66678
	Equal variances not assumed			-.030	6.370	.977	-.61742	20.54176	-50.18152	48.94667

Group Statistics

	kacang	N	Mean	Std. Deviation	Std. Error Mean
serum	1.00	13	75.6775	30.79052	8.53975
	2.00	27	94.1335	44.45129	8.55465

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means							
										95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
serum	Equal variances assumed	3.809	.058	-1.345	38	.186	-18.45599	13.71808	-46.22679	9.31480
	Equal variances not assumed			-1.527	32.884	.136	-18.45599	12.08758	-43.05164	6.13965

Group Statistics

	coklat	N	Mean	Std. Deviation	Std. Error Mean
serum	1.00	9	102.0835	37.15749	12.38583
	2.00	31	84.0858	41.80699	7.50876

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
serum	Equal variances assumed	.000	.993	1.163	38	.252	17.99774	15.47587	-13.33152	49.32700
	Equal variances not assumed			1.243	14.441	.234	17.99774	14.48414	-12.97891	48.97439

Group Statistics

	pedas	N	Mean	Std. Deviation	Std. Error Mean
serum	1.00	32	91.5448	41.00148	7.24811
	2.00	8	74.4975	40.99619	14.49434

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means							
										95% Confidence Interval of the Difference	
		F	Sig.	T	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper	
serum	Equal variances assumed	.073	.788	1.052	38	.300	17.04729	16.20687	-15.76181	49.85639	
	Equal variances not assumed			1.052	10.786	.316	17.04729	16.20558	-18.70736	52.80194	

Group Statistics

	rayah	N	Mean	Std. Deviation	Std. Error Mean
serum	1.00	7	102.8670	56.35028	21.29840
	2.00	33	85.0104	37.43576	6.51673

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means							
										95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
serum	Equal variances assumed	4.221	.047	1.046	38	.302	17.85662	17.06381	-16.68727	52.40050
	Equal variances not assumed			.802	7.164	.448	17.85662	22.27307	-34.56705	70.28028

Group Statistics

	ribu	N	Mean	Std. Deviation	Std. Error Mean
serum	1.00	5	98.6291	72.18830	32.28359
	2.00	35	86.6362	36.08227	6.09902

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper	
serum	Equal variances assumed	3.685	.062	.606	38	.548	11.99291	19.78991	-28.06967	52.05548	
	Equal variances not assumed			.365	4.290	.732	11.99291	32.85465	-76.84523	100.83105	

Group Statistics

	rsdr	N	Mean	Std. Deviation	Std. Error Mean
serum	1.00	12	70.6630	25.48761	7.35764
	2.00	28	95.6234	44.45568	8.40133

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
									95% Confidence Interval of the Difference	
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	Lower	Upper
serum	Equal variances assumed	5.990	.019	-1.813	38	.078	-24.96040	13.76791	-52.83208	2.91129
	Equal variances not assumed			-2.235	34.494	.032	-24.96040	11.16769	-47.64391	-2.27689

Correlations

		umur	serum	swab
umur	Pearson Correlation	1	-.328*	-.236
	Sig. (2-tailed)		.039	.143
	N	40	40	40
serum	Pearson Correlation	-.328*	1	.137
	Sig. (2-tailed)	.039		.398
	N	40	40	40
swab	Pearson Correlation	-.236	.137	1
	Sig. (2-tailed)	.143	.398	
	N	40	40	40

*. Correlation is significant at the 0.05 level (2-tailed).

Correlations

			umur	serum	swab
Spearman's rho	Umur	Correlation Coefficient	1.000	-.386[*]	-.154
		Sig. (2-tailed)	.	.014	.341
		N	40	40	40
	Serum	Correlation Coefficient	-.386[*]	1.000	.133
		Sig. (2-tailed)	.014	.	.414
		N	40	40	40
	Swab	Correlation Coefficient	-.154	.133	1.000
		Sig. (2-tailed)	.341	.414	.
		N	40	40	40

*. Correlation is significant at the 0.05 level (2-tailed).

ANOVA

Descriptives

Kode serum

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Minimum	Maximum
					Lower Bound	Upper Bound		
1.00	15	1.9333	.25820	.06667	1.7903	2.0763	1.00	2.00
2.00	20	1.9500	.22361	.05000	1.8453	2.0547	1.00	2.00
3.00	5	2.0000	.00000	.00000	2.0000	2.0000	2.00	2.00
Total	40	1.9500	.22072	.03490	1.8794	2.0206	1.00	2.00

ANOVA

Kode serum

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	.017	2	.008	.164	.002
Within Groups	1.883	37	.051		
Total	1.900	39			

Post Hoc Tests

Multiple Comparisons

Kode serum

LSD

(I) jfaktorrisiko	(J) jfaktorrisiko	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
1.00	2.00	-.01667	.07706	.025	-.1728	.1395
	3.00	-.06667	.11651	.000	-.3027	.1694
2.00	1.00	.01667	.07706	.025	-.1395	.1728
	3.00	-.05000	.11281	.018	-.2786	.1786
3.00	1.00	.06667	.11651	.000	-.1694	.3027
	2.00	.05000	.11281	.018	-.1786	.2786

ANOVA

Descriptives

Kode swab

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Minimum	Maximum
					Lower Bound	Upper Bound		
1.00	15	1.6667	.48795	.12599	1.3964	1.9369	1.00	2.00
2.00	20	1.5500	.51042	.11413	1.3111	1.7889	1.00	2.00
3.00	5	2.0000	.00000	.00000	2.0000	2.0000	2.00	2.00
Total	40	1.6500	.48305	.07638	1.4955	1.8045	1.00	2.00

ANOVA

Kode swab

	Sum of Squares	Df	Mean Square	F	Sig.
Between Groups	.817	2	.408	1.824	.176
Within Groups	8.283	37	.224		
Total	9.100	39			

Post Hoc Tests

Multiple Comparisons

Kode swab

LSD

(I) jfaktorrisiko	(J) jfaktorrisiko	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
1.00	2.00	.11667	.16161	.475	-.2108	.4441
	3.00	-.33333	.24434	.181	-.8284	.1617
2.00	1.00	-.11667	.16161	.475	-.4441	.2108
	3.00	-.45000	.23658	.065	-.9293	.0293
3.00	1.00	.33333	.24434	.181	-.1617	.8284
	2.00	.45000	.23658	.065	-.0293	.9293

Keterangan :
1 = 2-3 faktor risiko
2 = 4-5 faktor risiko
3 = ≥ 6 faktor risiko

Perbandingan kadar IL-12 serum berdasarkan jumlah faktor risiko

Faktor risiko	N	Kadar IL-12 swab Mean ± SD (Median)	P
2-3 faktor risiko (kelompok 1)	15	1.933 ± 0.258	
4-5 faktor risiko (kelompok 2)	20	1.950 ± 0.224	0.002
≥ 6 faktor risiko (kelompok 3)	5	2.000 ± 0.000	

Uji *one way* anova

Perbandingan kadar IL-12 serum antara dua kelompok berdasarkan jumlah faktor risiko

Kelompok	Perbedaan rerata	IK 95% Minimum	Maksimum	P
Klp 1 *vs* klp 2	-.0167	-.173	.140	0.025
Klp 1 *vs* klp 3	-.0667	-.303	.169	0.000
Klp 2 *vs* klp 3	-.0500	-.279	.179	0.018

Uji *Post Hoc*

Perbandingan kadar IL-12 swab berdasarkan jumlah faktor risiko

Faktor risiko	n	Kadar IL-12 serum Mean ± SD (Median)	P
2-3 faktor risiko (kelompok 1)	15	1.667 ± 0.488	
4-5 faktor risiko (kelompok 2)	20	1.550 ± 0.510	0.176
≥ 6 faktor risiko (kelompok 3)	5	2.000 ± 0.000	

Uji *one way* anova

Perbandingan kadar IL-12 swab antara dua kelompok berdasarkan jumlah faktor risiko

| Kelompok | Perbedaan rerata | IK 95% | | P |
		Minimum	Maksimum	
Klp 1 *vs* klp 2	.117	-.211	.444	0.475
Klp 1 *vs* klp 3	-.333	-.829	.162	0.181
Klp 2 *vs* klp 3	-.450	-.930	.029	0.065

Uji *Post Hoc*